Protara Therapeutics (FRA:1KPA) Moat Score: 2/10 (As of Aug. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:1KPA Protara Therapeutics Inc FRA:1KPA
38 GF Score
Price €3.41
! 3 Warning Signs
View Full Analysis

What is Protara Therapeutics Moat Score?

Protara Therapeutics FRA:1KPA +8.40% 38 Moat Score is 2 as of Aug. 02, 2026. GuruFocus rates FRA:1KPA with a GF Score™ of 38/100. The stock has 3 warning signs investors should review. Among 1,394 Biotechnology companies, Protara Therapeutics ranks better than 58.32% on this metric.

Protara Therapeutics has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Protara Therapeutics has No Moat: Protara Therapeutics operates in the biotech sector with high R&D costs and regulatory hurdles. The company lacks significant intellectual property or market leadership to establish a durable competitive advantage.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Protara Therapeutics might have No Moat - Very weak/transient advantages.

Protara Therapeutics  (FRA:1KPA) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Protara Therapeutics Moat Score Related Terms

FRA:1KPA vs TRDA, ACIU, OBIO: Moat Score Comparison

For the Biotechnology subindustry, Protara Therapeutics's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Protara Therapeutics Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Protara Therapeutics's Moat Score distribution charts can be found below:

* The bar in red indicates where Protara Therapeutics's Moat Score falls into.


FRA:1KPA
38GF Score
Protara Therapeutics Inc FRA:1KPA
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Protara Therapeutics (FRA:1KPA) has a Moat Score of 2 as of Aug. 02, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Protara Therapeutics ranks #581 out of 1394 companies in the Biotechnology industry, placing it in the top 41.7%.
Is Protara Therapeutics' Moat Score too high?
Protara Therapeutics' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Protara Therapeutics' value of 2 is 0% at this industry median. Based on the distribution chart, Protara Therapeutics ranks #581 out of 1394 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Protara Therapeutics has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Protara Therapeutics' Moat Score compare to TRDA and ACIU?
According to the Biotechnology industry distribution chart, Protara Therapeutics ranks #581 out of 1394 companies for Moat Score. This puts Protara Therapeutics in the upper half of its industry. The industry median Moat Score is 2.00. Protara Therapeutics' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,394 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Protara Therapeutics's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Protara Therapeutics's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Protara Therapeutics stock overvalued right now?
Protara Therapeutics (FRA:1KPA) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Protara Therapeutics' overall GF Score™ is 38/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Protara Therapeutics (FRA:1KPA), the current Moat Score is 2 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Protara Therapeutics Business Description

Other Exchanges TARA:USA
Address 345 Park Avenue South, 3rd Floor, New York, NY, USA, 10010
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.
38GF Score

Get the complete analysis for FRA:1KPA

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.41
Price